Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: Review of the literature

Journal of Medical Economics

Volumn 13, Issue 2, 2010, Pages 241-256

  Van Nooten, Floortje E ^a   Green, Julia ^a   Brown, Ruth ^a   Finkelstein, Fredric O ^b   Wish, Jay ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b YALE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Anemia; Chronic kidney disease; Economic burden; Health related quality of life burden; Non dialysis

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; CHRONIC KIDNEY DISEASE; COMORBIDITY; COMPARATIVE STUDY; CORRELATION ANALYSIS; COST OF ILLNESS; DAILY LIFE ACTIVITY; DISEASE CONTROL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; MEDICAL LITERATURE; PHYSICAL DISABILITY; QUALITY OF LIFE; REVIEW; UNITED STATES;

ANEMIA; COSTS AND COST ANALYSIS; HEMATINICS; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; QUALITY OF LIFE; UNITED STATES;

EID: 77953343626     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.484307     Document Type: Review

References (42)

1. Departments of Labor, Health and Human Services, and Education. Senate Report 109-1103 109th Congress, 1st Session 2006.
2. Melnikova I. Anaemia therapies. Nat Rev Drug Discov 2006; 5:627-628.
3. McClellan WM, Jurkovitz C, Abramson J. The epidemiology and control of anaemia among pre-ESRD patients with chronic kidney disease. EurJ Clin Invest 2005;35(Suppl 3):58-65.
4. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004;20:1501-1510. (Pubitemid 39361354)
5. Jungers PY, Robino C, Choukroun G, et al. Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients. Nephrol Dial Transplant 2002;17:1621-1627.
6. Obrador GT, Pereira BJ. Anaemia of chronic kidney disease: an under-recognized and under-treated problem. Nephrol Dial Transplant 2002;17(Suppl 11):44-46.
7. McFarlane SI, Chen SC, Whaley-Connell AT, et al. Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2008;51(4 Suppl 2):S46-55.
8. Lorber DL, Provenzano R, McClellan W. Prevalence and treatment of anemia with once-weekly epoetin alfa in patients with diabetes and chronic kidney disease. Endocr Pract 2006;12:506-513. (Pubitemid 46456037)
9. Ershler WB, Chen K, Reyes EB, et al. Economic burden of patients with anemia in selected diseases. Value Health 2005;8:629-638.
10. Lefebvre P, Duh MS, Buteau S, et al. Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease. J Am Soc Nephrol 2006;17:3497-3502.
11. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530.
12. Finkelstein FO, Story K, Firanek C, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. ClinJ Am Soc Nephrol 2009;4:33-38.
13. Wish J, Schulman K, Law A, et al. Healthcare expenditure and resource utilization in patients with anaemia and chronic kidney disease: a retrospective claims database analysis. Kidney Blood Press Res 2009;32:110-118.
14. Rasu RS, Manley HJ, Crawford T, et al. Undertreatment of anemia in patients with chronic kidney disease in the United States: analysis of national outpatient survey data. Clin Ther 2007;29:1524-1534.
15. London R, Solis A, Goldberg GA, et al. Health care resource utilization and the impact of anemia management in patients with chronic kidney disease. AmJ Kidney Dis 2002;40:539-548.
16. Kimmel PL, Greer JW, Milam RA, et al. Trends in erythropoietin therapy in the U.S. dialysis population: 1995 to 1998. Semin Nephrol 2000;20:335-344.
17. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
18. Maddux FW, Shetty S, del Aguila MA, et al. Effect of erythropoiesisstimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease. Ann Pharmacother 2007;41:1761-1769.
19. Moyneur E, Bookhart BK, Mody SH, et al. The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective. Dis Manag 2008;11:49-58.
20. Papatheofanis F, Bookhart BK, Muser E, et al. An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney disease. J Occup Environ Med 2008;50:584-589.
21. Perkins R, Olson S, et al. Impact of an anemia clinic on emergency room visits and hospitalizations in patients with anemia of CKD pre-dialysis. Nephrology Nursing 2007;34:167-182.
22. Provenzano R, Garcia-Mayol L, Suchinda P, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. Clin Nephrol 2004;61:392-405.
23. Alexander M, Kewalramani R, Agodoa I, et al. Association of anemia correction with health related quality of life in patients not on dialysis. Curr Med Res Opin 2007;23:2997-3008.
24. Cella D, Yount S, Sorensen M, et al. Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumatol 2005;32:811-819.
25. Revicki DA. Relationship between health utility and psychometric health status measures. Med Care 1992;30(5 Suppl):MS274-282.
26. Muirhead N, Cattran DC, Zaltzman J, et al. Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol 1994;5:1216-1222.
27. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
28. Abu-Alfa AK, Sloan L, Charytan C, et al. The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin 2008;24:1091-1100.
29. Agarwal R, Rizkala AR, Bastani B, et al. A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006;26:445-454.
30. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071-2084.
31. Benz R, Schmidt R, Kelly K, et al. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol 2007;2:215-221.
32. Provenzano R, Bhaduri S, Singh AK. PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005;64:113-123. (Pubitemid 41079007)
33. Lefebvre P, Vekeman F, Sarokhan B, et al. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin 2006; 22:1929-1937. (Pubitemid 44663398)
34. Revicki DA, Brown R, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25:548-554.
35. Kleinman KS, Schweitzer SU, Perdue ST, et al. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebocontrolled trial. Am J Kidney Dis 1989;14:486-495.
36. Sobrero A, Puglisi F, Guglielmi A, et al. Fatigue: a main component of anemia symptomatology. Semin Oncol 2001;28(2 Suppl 8):15-18.
37. Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int 2009;75:15-24.
38. Gandra SR, Finkelstein FO, Bennett AV, et al. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. AmJ Kidney Dis 2010;55:519-534.
39. Unger EF, Thompson AM, Blank MJ, et al. Erythropoiesis-stimulating agents - time for a reevaluation. N Engl J Med 2010;362:189-192.
40. Odden MC, Whooley MA, Shlipak MG. Association of chronic kidney disease and anaemia with physical capacity: the heart and soul study. JAm Soc Nephrol 2004;15:2908-2915.
41. Lindgren C. New survey provides insight into CKD, exhaustion, anaemia. Nephrol News Issues 2003;17:29-31.
42. Ware JE, Kosinski M, Dewey JE. How to score Version Two of the SF-36 Health Survey. Lincoln, RI: Quality Metric, Incorporated, 2000.